Article Contents ::
- 1 The Brand Name FLUSTA Has Generic Salt :: Fluconazole
- 2 FLUSTA Is From Company Stalwart Priced :: Rs. 12.5
- 3 FLUSTA have Fluconazole is comes under Sub class Anti Fungals of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Anti Fungals
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name FLUSTA Has Generic Salt :: Fluconazole
FLUSTA Is From Company Stalwart Priced :: Rs. 12.5
FLUSTA have Fluconazole is comes under Sub class Anti Fungals of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Anti Fungals
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Fluconazole | TAB | Rs. 12.5 | 1 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 1 |
FLUSTA | Stalwart | 150MG | 1 | Rs. 12.5 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Stalwart :: FLUSTA | Fluconazole | Anti Infectives | Anti Fungals |
Indications for Drugs ::
Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis
Drug Dose ::
Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. Candidal balanitis; Vag candidiasis 150 mg as a single dose. Dermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day. Child over 1 year – superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) – 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years – max. 400 mg daily). Renal impairment: Haemodialysis patients: Usual dose given after each session. CrCl (ml/min) <50 and not receiving dialysis 50% of the usual dose. >50 Usual dose.
Contraindication ::
Hypersensitivity.
Drug Precautions ::
Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.
Drug Side Effects ::
Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia. Potentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.
Pregnancy category ::
4
Drug Mode of Action ::
Fluconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity, thus inhibiting cell membrane formation of susceptible fungi including B. dermatitidis, Candida spp., C. immitis, C. neoformans, Epidermophyton spp., H. capsulatum, Micosporum spp., Trichophyton spp.
Drug Interactions ::
May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam). Potentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.